CureVac: News from the board of the stock exchange candidate

Stock exchange candidate CureVac reports changes on the board: Franz-Werner Haas becomes the company’s new CEO. The former Sygnis manager was previously acting CEO and Chief Operating Officer (COO) at the company. In addition, Igor Splawski should take on the position of Chief Scientific Officer on the Executive Board with immediate effect, the biotech company announced on Tuesday. Splawski will be responsible for all of the company’s mRNA biology research.

CureVac is part of the group of companies currently working on a vaccine against the SARS-CoV-2 virus, the causative agent of the COVID-19 pandemic. In the future, the Tübingen shares are to be traded on the NASDAQ – an IPO on the US technology exchange could be planned for October after the company initially targeted July. The prospectus has now been approved.

Dietmar Hopp currently has a stake in the company through his dievini Holding. It was recently reported that, among other things, the state-owned credit institution for reconstruction and the British pharmaceutical company GlaxoSmithKline were involved in a pre-IPO round of financing at CureVac participate.


Related Articles

Back to top button